Pfizer‘s Q3 2015 earnings reinforced our belief that the last quarter was a turning point for the company’s business. The third quarter built upon that momentum, and we saw good growth across key drugs including Prevnar, Eliquis, Ibrance and Lyrica. However, the longer term growth is likely to come from new drugs or the extension of current drugs for additional indications. Considering the recent pipeline activity, acquisition of Hospira, and the company’s quest for more strategic alliances, we believe that Pfizer may launch some successful drugs in the next 5 years. While the currency movement has acted as a dampener, the underlying operational growth is reviving.
from Forbes Real Time http://onforb.es/1NazzBs
Aucun commentaire:
Enregistrer un commentaire